Monograph Details
|
|
Dermatological Disorders
> Miscellaneous dermatological conditions
|
|
EFUDEX |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimetabolite. |
| Generic Name |
|
Fluorouracil 2%, 5%; soln. |
| Also |
|
• EFUDEX CREAM
|
| Indications |
|
Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see literature. |
| Children |
|
Not recommended. |
| Adults |
|
Keratoses: Apply twice daily until erosion occurs (usually 2–4 wks). Basal cell carcinoma (5% only): Apply twice daily, usually for 3–6 weeks (obliteration may take 10–12 weeks). |
| Contraindications |
|
Dihydropyrimidine dehydrogenase (DPD) deficiency. Pregnancy (Cat.X). |
| Precautions |
|
Apply cautiously near eyes, nose, mouth. Avoid mucous membranes, occlusion, ulcerated/inflamed skin, exposure to UV light. Wash hands after application if fingers were used. Notify patients of expected skin reaction. Biopsy unresponsive lesions. Nursing mothers: not recommended. |
| Adverse Reactions |
|
Pain or burning at application site, pruritus, irritation, hyperpigmentation. |
| How Supplied |
Soln—10mL (w. drop dispenser)
Crm—25g |
|
|
|
|
